Only in Titles

           Search results for: Mycoplasma pneumoniae IgA ELISA kit   

paperclip

#20701743   2010/09/06 Save this To Up

Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae.

Mycoplasma pneumoniae is responsible for acute respiratory tract infections (RTIs) common in children and young adults. As M. pneumoniae is innately resistant to beta-lactams antibiotics usually given as the first-line treatment for RTIs, specific and early diagnosis is important in order to select the right treatment. Serology is the most used diagnostic method for M. pneumoniae infections.

1605 related Products with: Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae.

AtpB | beta subunit of AT AtpB | beta subunit of AT ATP synthase H+ transport pCMVLuxB Mammalian LuxB E Anti-ATPase, (Na(+) K(+)) Anti ATPase, (Na(+) K(+)) anti GSK3 Beta IgG2a (mon BACTERIOLOGY MYCOPLASMA P MYCOPLASMA PNEUMONIAE M12 succinate-CoA ligase, GDP ATPase beta3(Na+ K+) anti ATP synthase C mature ant

Related Pathways

paperclip

#12376023   2002/10/11 Save this To Up

Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD.

A prospective study was conducted to identify and characterize hospitalizations for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with serologic evidence of infection with Mycoplasma pneumoniae (Mp). Two hundred forty hospitalizations for AECOPD were included in a 17-month prospective study. Paired sera were obtained for each of the hospitalizations and were tested serologically for Mp using a commercial enzyme immunoassay (EIA) kit. Only significant changes, according to the formula in the manufacturer's instructions, in antibody titers for IgM and/or IgG and/or IgA were considered diagnostic for Mp infection. In 34 hospitalizations (14.2%) the serologic tests for Mp were positive (MpH). In 29 of these hospitalizations (85%) a significant change in IgA was found. In 11 of these hospitalizations (32%) the only change identified was in IgA. In 24 MpH (71%) there was serologic evidence for infection with at least one other respiratory pathogen. In comparison to the 206 hospitalizations without serologic evidence of infection with Mp, MpH had higher rates of inhaled steroid therapy (41% vs. 24%, p = 0.033) and a longer time interval between the appearance of dyspnea and hospitalization (6.6 +/- 3.8 days vs. 5.0 +/- 3.5 days, p = 0.012). There were no significant differences between these two groups in a broad spectrum of patient- and exacerbation-related clinical variables. Specific antibiotic therapy for Mp in the MpH group did not shorten the hospital stay. Serologic evidence of Mp infection is common in patients hospitalized for AECOPD, and is usually based on changes in specific IgA antibody titers. In most MpH another respiratory pathogen can be identified. The vast majority of clinical characteristics are the same in patients with and without serologic evidence of infection with Mp. The practical implications of these findings should be clarified in further studies.

2872 related Products with: Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD.

BACTERIOLOGY MYCOPLASMA P MYCOPLASMA PNEUMONIAE M12 Infection diseases: Heli Infection diseases: Heli Liver cancer tissue array Liver tissue cancer tissu Hepatocellular carcinoma Ofloxacin CAS Number [824 Mycoplasma pneumoniae IgA Mycoplasma pneumoniae IgG Mycoplasma pneumoniae IgM Mycoplasma pneumoniae Ant

Related Pathways

  •  
  • No related Items